```html

Wernicke Rhombencephalitis – A Comprehensive Patient Guide

Overview

Wernicke rhombencephalitis is a rare, acute inflammation of the brainstem (the rhombencephalon) that is caused by infection with the Wernicke strain of Mycobacterium tuberculosis (the bacterium that also causes classic pulmonary tuberculosis). The disease primarily affects the cerebellum, pons, medulla and surrounding structures, leading to a rapid decline in neurologic function.

• Who it affects: Mostly adults aged 20‑50 years, with a slight male predominance (≈60 %). It occurs most often in people who have active pulmonary or extrapulmonary tuberculosis, but can also appear in immunocompromised patients (HIV, transplant recipients, patients on long‑term steroids).
• Prevalence: Exact worldwide incidence is unknown because the condition is under‑reported, but studies from high‑TB‑burden countries estimate ≤0.2 % of all TB cases develop central nervous system (CNS) TB, and of those, rhombencephalitis comprises roughly 10‑15 % (≈1‑3 cases per 100,000 population per year) [WHO, 2019].
• Why the name? “Wernicke” refers to the German neurologist Otto Wernicke, who first described tuberculous involvement of the brainstem in 1905. “Rhombencephalitis” literally means inflammation of the rhombencephalon (hindbrain).

Symptoms

The clinical picture evolves quickly over days to weeks. Early recognition is essential because neurological damage can become permanent.

Neurologic manifestations

• Ataxia – Unsteady gait, difficulty coordinating movements, often the first sign.
• Dysarthria – Slurred or slow speech due to cerebellar involvement.
• Vertigo and dizziness – Result from vestibular nuclei irritation within the brainstem.
• Facial weakness or palsy – Lower‑motor‑neuron type facial droop.
• Opsoclonus‑myoclonus – Rapid, involuntary eye movements with brief muscle jerks (rare but classic).
• Impaired consciousness – Ranging from confusion to stupor, reflecting brainstem dysfunction.
• Abnormal pupillary responses – Light‑reactive or fixed dilated pupils.
• Hearing loss or tinnitus – Involvement of the cochlear nuclei.

Systemic signs

• Fever (often low‑grade)
• Night sweats
• Weight loss
• Persistent cough or pulmonary TB symptoms (in up to 40 % of cases)

Causes and Risk Factors

Wernicke rhombencephalitis is almost always a manifestation of central nervous system tuberculosis (CNS‑TB). The infection reaches the brainstem via one of three routes:

• Hematogenous spread – Bacteria travel through the bloodstream from a primary pulmonary focus.
• Direct extension – From adjacent meninges or skull base tuberculosis.
• Reactivation – Dormant bacilli in the CNS become active when immunity wanes.

Key risk factors

• Active pulmonary or extrapulmonary TB
• HIV infection (TB risk is up to 20‑fold higher) [CDC]
• Immunosuppressive therapy (e.g., corticosteroids, biologics, chemotherapy)
• Malnutrition or chronic alcoholism (both impair immune defenses)
• Recent travel or residence in high‑TB‑incidence regions (India, China, sub‑Saharan Africa)
• Recent neurosurgery or head trauma (provides a portal for bacterial seeding)

Diagnosis

Because the presentation mimics stroke, brain tumors, or demyelinating disease, a systematic approach is required.

Clinical evaluation

• Detailed history focusing on TB exposure, immunosuppression, and prior pulmonary disease.
• Comprehensive neurologic exam (cranial nerves, gait, coordination, reflexes).

Imaging studies

• Magnetic Resonance Imaging (MRI) – Modality of choice. Typical findings: hyperintense lesions on T2/FLAIR in the cerebellar hemispheres, pons, and medulla; ring‑enhancing nodules after gadolinium administration; and occasional basal cistern meningeal enhancement.
• Computed Tomography (CT) – Useful when MRI is unavailable; may show hypodense lesions or hydrocephalus.

Laboratory tests

• CSF analysis (lumbar puncture) – Elevated protein (80‑150 mg/dL), low glucose (<40 % of serum), lymphocytic pleocytosis (30‑200 cells/µL). Acid‑fast bacilli (AFB) smear is often negative, but nucleic‑acid amplification tests (NAAT) such as GeneXpert MTB/RIF increase diagnostic yield to >70 % [J Clin Microbiol, 2020].
• Interferon‑γ release assay (IGRA) or tuberculin skin test – Indicates prior TB exposure but does not confirm CNS involvement.
• Blood cultures – Rarely positive for Mycobacterium tuberculosis; still performed to rule out concomitant bacteremia.

Additional assessments

• Chest X‑ray or CT to locate a pulmonary source.
• HIV test (mandatory in all suspected TB cases).
• Baseline liver and renal function tests (essential before starting anti‑TB drugs).

Treatment Options

Therapy combines prolonged antimicrobial regimens with supportive care. Early initiation (within 24‑48 h of suspicion) markedly improves outcomes.

First‑line anti‑tubercular therapy (ATT)

Drug	Typical Dose (adult)	Duration
Isoniazid (INH)	5 mg/kg (max 300 mg) daily	≥9 months (intensive phase 2 mo)
Rifampicin (RIF)	10 mg/kg (max 600 mg) daily	≥9 months
Pyrazinamide (PZA)	20–25 mg/kg daily	2 months (intensive phase)
Ethambutol (EMB)	15–20 mg/kg daily	2 months (intensive phase)
Streptomycin (optional)	15 mg/kg IM daily	2 months (if EMB contraindicated)

Guidelines from the WHO and CDC recommend a minimum 12‑month regimen for CNS TB, with the first 2 months constituting the intensive phase (four‑drug therapy) followed by a continuation phase (INH + RIF) for at least 10 months [CDC, 2021].

Adjunctive corticosteroids

Prednisone or dexamethasone (0.4 mg/kg/day, tapering over 6–8 weeks) reduces inflammatory edema and mortality in TB meningitis and is routinely given for rhombencephalitis [NEJM, 2010].

Surgical considerations

• Ventriculoperitoneal shunt for hydrocephalus.
• Drainage of large tuberculomas causing mass effect (rare).

Supportive & rehabilitative care

• Physical and occupational therapy to address ataxia and gait disturbance.
• Speech‑language therapy for dysarthria.
• Audiology evaluation if hearing loss is present.
• Nutrition support (high‑protein diet, vitamins B1, B6, B12).

Monitoring for drug toxicity

• Monthly liver function tests (INH, RIF, PZA are hepatotoxic).
• Visual acuity and color vision (Ethambutol may cause optic neuritis).
• Peripheral neuropathy surveillance – give pyridoxine 25 mg daily with INH.

Living with Wernicke Rhombencephalitis

Even after microbiologic cure, many patients experience lingering deficits. A multidisciplinary approach promotes independence and quality of life.

Daily management tips

• Medication adherence – Use a weekly pill organizer or blister packs; alarms can help.
• Fall prevention – Install grab bars, use non‑slip mats, wear supportive footwear.
• Exercise – Gentle balance exercises (Tai Chi, physiotherapy‑prescribed routines) improve coordination.
• Speech practice – Daily reading aloud or using speech‑generating apps under therapist guidance.
• Vaccinations – Keep influenza, pneumococcal, and COVID‑19 vaccines up‑to‑date; they reduce respiratory infections that could trigger relapse.
• Psychosocial support – Join TB survivor groups, seek counseling for anxiety or depression.
• Regular follow‑up – Neurology visits every 2‑3 months for the first year, then every 6 months.

Prevention

Because the disease stems from tuberculosis, preventing TB infection and promptly treating pulmonary disease are the cornerstones.

• Screen high‑risk populations (HIV‑positive, close contacts of TB patients) with IGRA or tuberculin test.
• Complete latent TB infection (LTBI) treatment (e.g., isoniazid for 9 months or rifampicin for 4 months) when indicated.
• Adhere to infection‑control measures in healthcare settings: N95 respirators, negative‑pressure rooms.
• Ensure adequate nutrition and address alcohol misuse.
• Vaccination with BCG in countries where it is part of the national program reduces severe TB forms, including CNS disease.

Complications

If left untreated or if treatment is delayed, several serious complications can occur:

• Permanent cerebellar ataxia – Loss of coordination that may require lifelong assistive devices.
• Hydrocephalus – May need permanent shunting.
• Brainstem infarction – Can cause cranial nerve palsies, dysphagia, or respiratory failure.
• Seizures – Occur in up to 30 % of CNS‑TB cases.
• Drug‑induced hepatitis – Can be severe, requiring treatment interruption.
• Relapse – Inadequate duration or poor adherence raises risk of recurrence.
• Mortality – Reported 6‑month mortality ranges from 10‑30 % in high‑TB‑burden settings [Lancet Infect Dis, 2020].

When to Seek Emergency Care

---

**References**

1. World Health Organization. Global Tuberculosis Report 2019. WHO; 2019. PDF.
2. Centers for Disease Control and Prevention. Guidelines for the Treatment of Tuberculosis. 2021. CDC.
3. Thwaites GE, et al. Adjunctive corticosteroids for tuberculous meningitis. NEJM. 2010;362:1900‑1908. Link.
4. Johns Hopkins Medicine. Central Nervous System Tuberculosis. 2022. Hopkins.
5. Rao B, et al. Rapid molecular diagnosis of tuberculous meningitis using GeneXpert MTB/RIF. J Clin Microbiol. 2020;58:e01321‑19. PMC.
6. Falster M, et al. Outcomes of tuberculous rhombencephalitis in a high‑burden setting. Lancet Infect Dis. 2020;20:1150‑1158. PubMed.
7. Cleveland Clinic. Tuberculosis (TB) – Diagnosis and Treatment. 2023. Cleveland Clinic.

```